outline
DESCRIPTION
WCLC 2013: Update On SCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester Manchester, UK [email protected]. Outline. Background Key studies Conclusion. Background. Aggressive disease Poor prognosis - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/1.jpg)
WCLC 2013:Update On SCLC
Raffaele Califano
Department of Medical Oncology The Christie and University Hospital of South
ManchesterManchester, UK
![Page 2: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/2.jpg)
Outline
Background
Key studies
Conclusion
![Page 3: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/3.jpg)
Background
Aggressive disease
Poor prognosis
Targeted agents have all failed so far...
No real progress in 20 years
![Page 4: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/4.jpg)
Key Studies
First-line treatment:Seckl et al (Abs O21.01)Glisson et al (Abs O21.05)
Pre-treated patients:Havel et al (Abs O21.06)
![Page 5: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/5.jpg)
Multicentre Phase III Randomised Multicentre Phase III Randomised Double Blind Placebo Controlled Double Blind Placebo Controlled Trial of Pravastatin added to First Trial of Pravastatin added to First Line Standard Chemotherapy in Line Standard Chemotherapy in SCLCSCLC
LungSt r
Michael J Seckl on behalf of the LungStar collaborators
![Page 6: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/6.jpg)
Statins:Kill SCLC in vitro + in vivo/additive with
chemo
May prevent cancer
Danish study: Longer OS for ca pts on statins
HCC: Pravastatin doubles survival
Rationale
![Page 7: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/7.jpg)
Placebo
Pravastatin 40 mg
ODPreviously untreated
LS/ ES SCLC, PS 0-3
No statins < 12m
(n=846)
R
Platinum/Etoposide plus placebo
Platinum/Etoposide plus pravastatin 40
mg OD
Primary endpoint: OS
Study Design
1:1 For 2 years
![Page 8: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/8.jpg)
Statistics
•Original sample size:•1300 patients (90% power, 5% significance level) to detect an increase from 10% to 15% in 2-yr survival with pravastatin •Equivalent to a median survival increase from 9 to 11 months in ES and 15 to 19 months in LS
•Revised sample size:•Reduced to 80% power, 5% significance level•842 patients with 792 events corresponds to detecting a HR of 0.82
![Page 9: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/9.jpg)
Baseline Characteristics
Pravastatin(N=422)
Placebo(N=424)
P-value
Male 219 (52%) 214 (51%) 0.681
Limited Stage 179 (42%) 178 (42%) 0.889
ECOG 0-1 316 (75%) 315 (74%) 0.813
Age (yrs) median [range]
64[41-86]
64[42-85] 0.621
Ipsiltateral SCN 97 (23%) 105 (25%) 0.573
Carboplatin/Etop.Cisplatin/Etop.
365 (87%) 57 (13%)
385 (91%)39 (9%)
0.0510.101
![Page 10: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/10.jpg)
Pravastatin PlaceboMedian (mos) [95% CI]
10.7 [10.0-11.8]
10.8 [10.0-12.8]
1 Year OS [95% CI] 45.0% [40.3-49.8]
47.2% [42.4-51.9]
2 Year OS [95% CI] 15.9% [12.3-19.5]
17.3% [13.6-21.0]
HR: 1.08 (0.93-1.25) P=0.339
Overall Survival
![Page 11: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/11.jpg)
Pravastatin Placebo
Median (mos) [95% CI]
7.8 [7.1-8.5] 7.4 [6.9-8.0]
1 Year PFS [95% CI] 26.8% [22.6-31.1]
27.3% [23.0-31.6]
2 Year PFS [95% CI] 10.0% [7.0-13.1] 11.8% [8.5-15.0]
HR: 1.03 (0.89-1.18) P=0.703
Progression-free Survival
![Page 12: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/12.jpg)
Toxicity
![Page 13: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/13.jpg)
Pravastatin Ineffective
Sub-group analyses / Translational studies?
A lot of patients/money wasted!
Conclusion/Comments
![Page 14: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/14.jpg)
A Randomized Phase 2 Study of Ganitumab or Rilotumumab with
Platinum-Based Chemotherapy as First-Line Treatment for Extensive-
Stage SCLC
B. Glisson, et al
![Page 15: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/15.jpg)
IGF1-RInhibition sensitizes cell lines to etoposide and carboplatin
High levels correlate with short survival
MET Expressed and functional in SCLC
Mutant in a subset of SCLC cell lines and tumor samples
Ganitumab and rilotumumabFully human mAbs targeting IGF1-R and hepatocyte growth factor (HGF)/scatter factor
Rationale
![Page 16: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/16.jpg)
Placebo
Ganitumab
Previously untreated ES SCLC,
PS 0-1No thrombosis
No diabetes(n=185)
R
Platinum/Etoposide plus placebo
Platinum/Etoposide plus Ganitumumab
Primary endpoint: OS
Study Design
1:1:1
Until PD
RilotumumabPlatinum/Etoposide plus Rilotumumab
![Page 17: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/17.jpg)
Full analysis setGanitumab
(n = 62)Rilotumumab
(n = 62)Placebo(n = 61)
Median age (range), y 60 (45–79) 61 (42–74) 61 (33–76)
Male, n (%) 48 (77) 47 (76) 47 (77)
Extensive disease stage at initial diagnosis, n (%)
60 (97) 62 (100) 58 (95)
ECOG performance status,a n (%)
0 13 (21) 19 (31) 12 (20)
1 48 (77) 43 (69) 49 (80)
Median baseline LDH (U/L) 345 388 432
Patients who received carboplatin, n (%) 41 (66) 40 (65) 40 (66)
Patients who received cisplatin, n (%) 21 (34) 22 (35) 21 (34)
Safety analysis setGanitumab
(n = 59)Rilotumumab
(n = 61)Placebo(n = 59)
Patients receiving prophylactic cranial irradiation, n (%)
34 (58) 25 (41) 27 (46)
Patients’ Charactheristics
![Page 18: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/18.jpg)
Ganitumab
(n = 62)
Rilotumumab
(n = 62)
Placebo(n = 61)
Complete response, n (%)
0 2 (3) 1 (2)
Partial response, n (%)
39 (63) 40 (65) 35 (57)
Stable disease, n (%) 13 (21) 12 (19) 16 (26)
Overall Response Rate
![Page 19: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/19.jpg)
Overall Survival
Ganitumab
(n = 62)
Rilotumumab
(n = 62)
Placebo(n = 61)
Median (95% CI), mo
10.7 (8.1–14.1)
12.2 (8.8–14.6)
10.8(9.4–11.9)
Adjusted HRa
(95% CI)
1.01(0.67–1.52)
0.91(0.60–1.39)
Progression Free Survival
Ganitumab
(n = 62)
Rilotumumab
(n = 62)
Placebo(n = 61)
Median (95% CI), mo
5.5(4.4–5.7)
5.4(4.4–5.7)
5.4(4.6–5.8)
Adjusted HRa
(95% CI)
1.03(0.70–1.52)
1.03(0.69–1.52)
![Page 20: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/20.jpg)
Ganitumab (n = 59)
Rilotumumab
(n = 61)
Placebo(n = 59)
Patients reporting ≥ 1 grade ≥ 3 AE, n (%) 41 (69) 44 (72) 47 (80)
Grade ≥ 3 AEs of interest reported in ≥ 1 patient, n (%)
Neutropenia 31 (53) 33 (54) 36 (61)Thrombocytopenia 8 (14) 9 (15) 2 (3)Venous thromboembolic events 3 (5) 2 (3) 2 (3)Hyperglycemia 3 (5) 2 (3) 1 (2)IP-related hepatic disorders 0 2 (3) 1 (2)Infusion reaction 1 (2) 0 0Arterial embolic/thromboembolic events
0 1 (2) 0
Cerebrovascular events 0 1 (2) 0
Gastric hemorrhage 0 0 1 (2)
Patients with a grade 5 AE, n (%) 7 (12) 6 (10) 3 (5)
Adverse Events
![Page 21: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/21.jpg)
Only available for IGF axis (Serum)
Low IGFBP-2 levels associated with increased response (but no OS) on ganitumab arm
Tumor biomarkers pending
Biomarker analysis
![Page 22: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/22.jpg)
No improvement in ORR, PFS, or OS
No pre-clinical data for activity in SCLC
Experimental agents only active in a targeted population?
Conclusion/Comments
![Page 23: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/23.jpg)
MLN8237 (ALISERTIB), An Investigational Selective Aurora
A Kinase (AAK) Inhibitor, In patients With
Relapsed/Refractory SCLC: PHASE 2 RESULTS
Havel et al
![Page 24: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/24.jpg)
Key mitotic regulator AAK is amplified or overexpressed in a variety of solid tumors
Inhibition of AAK results in:Chromosome misalignment and instabilityAbnormal spindle formationReduction in astral microtubule length/stability
Small molecule inhibitor of AAK with single-agent antitumor activity
Preclinical data support combination with taxanes, rituximab and other agents
Control
treated treated
treated
α−tubulin, DNA, Centrosomes
untreated
Rationale
![Page 25: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/25.jpg)
RP2D determined duringphase 1 portion of study
RP2D:MLN8237 50 mg BID for 7 days (21-day cycles)
Treatment for24 months, or until PD or unacceptable
toxicity
Study Design
SCLCN=45
H&NN=45
BreastN=45
GastricN=45
NSCLCN=45 ES SCLC
ECOG PS 0–1
≤2 prior lines
No symptomatic brain mets
Primary endpoint: ORR
![Page 26: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/26.jpg)
*Based on safety population (n=60) Data as of April 2013
All SCLC arm patients [response-evaluable]
(n=48)
Median age, years (range) 62 (46–76)
Male, n (%) 24 (50)
Race, n (%)WhiteBlack or African American
45 (94)3 (6)
Median time since diagnosis, years (range)*
1.0 (0.4–4.4)
ECOG PS, n (%)01
13 (27)35 (73)
Prior lines of therapy, n (%)1 2
25 (52)23 (48)
Demographics
![Page 27: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/27.jpg)
All patients (n=48)
Chemo-sensitive (n=36)
Chemo-refractory
(n=12)
First line, n (%)
Platinum/etoposide 45 (94) 33 (92) 12 (100)
Platinum/irinotecan 2 (4) 2 (5) –
Other 1 (2) 1 (3) –
Second line, n (%) n=23 n=19 n=4
Rechallenge 13 (56) 12 (63) 1 (25)
Topotecan 3 (13) 2 (11) 1 (25)
Paclitaxel 2 (9) 1 (5) 1 (25)
Platinum/Irinotecan 3 (13) 2 (11) 1 (25)
Other 2 (9) 2 (11) –Data as of April 2013
Previous Treatment
![Page 28: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/28.jpg)
Data as of September 2013
Efficacy and SafetyAll SCLC Patients
(N=48)Chemo-
sensitive (n=36)
Chemo-refractory
(n=12)
Median Cycles, n (range)
2 (1–15) 3.5 (1–15) 2 (2–6)
Best Response, n (%)ORR (PR)SDPD
10 (21)16 (33)22 (46)
7 (19)13 (36)16 (44)
3 (25)3 (25)6 (50)
Median PFS, months 2.11 2.58 1.74
Median TTP, months 2.6 2.8 1.4
Median DOR, months 4.1 4.4 3.1
Most common (≥5 %) grade ≥3 AEs, n (%)
Neutropenia 18 (30)
Anemia 10 (17)
Thrombocytopenia 6 (10)
Most common (≥5 %) grade ≥3 AEs, n (%)
Decreased WBC 7 (12)
Confusional state 4 (7)
Febrile neutropenia 5 (8)
![Page 29: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/29.jpg)
Biomarker analysis
53 tumor tissues available (6 responders, 2 SCLC)
Candidate biomarkers: amplification of Myc family genes and Aurora A, Ki-67)
Whole exome sequencing
![Page 30: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/30.jpg)
Mutated genes found in responders
Mutational landscape of SCLC
R
NR
R
NR
Highly mutated
Among 527 frequently mutated genes reported in SCLC, 122 genes found to be mutated in at least 1/6 patients
Fisher’s exact test identified 8 mutated genes associated with responders
Gene
Gene
Patie
nt
Patie
ntWhole exome sequencing:
Preliminary analysis
![Page 31: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/31.jpg)
Manageable safety profile
Activity similar to active agents in patients with relapsed SCLC
RPh2 study: Paclitaxel +/-MLN8237 to start soon
Conclusion/Comments
![Page 32: Outline](https://reader035.vdocuments.mx/reader035/viewer/2022062500/5681579d550346895dc5332e/html5/thumbnails/32.jpg)
No practice changing data
Need better understanding of molecular biology
Need tissue and possibly serum/plasma to be mandatory in trials
Take Home message